ATE544455T1 - Zusammensetzungen und verfahren für die krebsbehandlung - Google Patents

Zusammensetzungen und verfahren für die krebsbehandlung

Info

Publication number
ATE544455T1
ATE544455T1 AT07862970T AT07862970T ATE544455T1 AT E544455 T1 ATE544455 T1 AT E544455T1 AT 07862970 T AT07862970 T AT 07862970T AT 07862970 T AT07862970 T AT 07862970T AT E544455 T1 ATE544455 T1 AT E544455T1
Authority
AT
Austria
Prior art keywords
compositions
methods
cancer treatment
cancer
treatment
Prior art date
Application number
AT07862970T
Other languages
English (en)
Inventor
Hanno Roder
Original Assignee
Tautatis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tautatis Inc filed Critical Tautatis Inc
Application granted granted Critical
Publication of ATE544455T1 publication Critical patent/ATE544455T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT07862970T 2006-12-14 2007-12-14 Zusammensetzungen und verfahren für die krebsbehandlung ATE544455T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87501306P 2006-12-14 2006-12-14
PCT/US2007/025692 WO2008076394A1 (en) 2006-12-14 2007-12-14 Compositions and methods for the treatment of cancer

Publications (1)

Publication Number Publication Date
ATE544455T1 true ATE544455T1 (de) 2012-02-15

Family

ID=39536630

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07862970T ATE544455T1 (de) 2006-12-14 2007-12-14 Zusammensetzungen und verfahren für die krebsbehandlung

Country Status (7)

Country Link
US (2) US8022056B2 (de)
EP (1) EP2124554B1 (de)
JP (1) JP2010513287A (de)
AT (1) ATE544455T1 (de)
AU (1) AU2007334381B2 (de)
CA (1) CA2672650C (de)
WO (1) WO2008076394A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004025726B4 (de) * 2004-05-26 2006-07-06 Roder, Hanno, Dr. Verwendung eines spezifischen K252a-Derivats zur Verhinderung oder Behandlung der Alzheimerschen Krankheit
WO2008076394A1 (en) * 2006-12-14 2008-06-26 Tautatis, Inc. Compositions and methods for the treatment of cancer
WO2010085799A2 (en) * 2009-01-26 2010-07-29 Tautatis, Inc. Compositions and method for the treatment of parkinson's disease
WO2013059320A1 (en) * 2011-10-17 2013-04-25 Board Of Regents, The University Of Texas System Treatment of cancers with mutant npm1 with mek inhibitors
CN107936043B (zh) * 2017-12-11 2019-01-01 南京诺赛德生物技术有限公司 一种具有抗肿瘤活性物质及其合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG18188A (en) * 1986-05-01 1992-09-30 Pfizer Ltd Process for preparation anti-arhythmia agents
WO1997005140A1 (en) * 1995-07-31 1997-02-13 Novartis Ag Trindene compounds
NZ333536A (en) 1996-08-22 1999-10-28 Bristol Myers Squibb Co Cytotoxic amino sugar and related sugar derivatives of indolopyrrolocarbazoles, and use as antitumour agents
EP1044203B1 (de) * 1997-12-31 2003-03-12 Cephalon, Inc. 3'-epi k-252a derivate
US6013646A (en) * 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
US6841567B1 (en) * 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US7129250B2 (en) * 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
US6677450B2 (en) * 2000-10-06 2004-01-13 Bristol-Myers Squibb Company Topoisomerase inhibitors
JP2007513967A (ja) * 2003-12-11 2007-05-31 セラヴァンス， インコーポレーテッド 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物
DE102004025726B4 (de) * 2004-05-26 2006-07-06 Roder, Hanno, Dr. Verwendung eines spezifischen K252a-Derivats zur Verhinderung oder Behandlung der Alzheimerschen Krankheit
WO2008076394A1 (en) * 2006-12-14 2008-06-26 Tautatis, Inc. Compositions and methods for the treatment of cancer

Also Published As

Publication number Publication date
EP2124554A4 (de) 2009-12-30
EP2124554B1 (de) 2012-02-08
US20080255087A1 (en) 2008-10-16
CA2672650C (en) 2015-09-08
US8022056B2 (en) 2011-09-20
CA2672650A1 (en) 2008-06-26
AU2007334381A1 (en) 2008-06-26
AU2007334381B2 (en) 2014-02-13
JP2010513287A (ja) 2010-04-30
EP2124554A1 (de) 2009-12-02
US20120202789A1 (en) 2012-08-09
WO2008076394A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
FR21C1063I1 (fr) Traitement combiné de tumeurs exprimant la cd38
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
DK1853602T3 (da) Kemiske forbindelser
CY1108275T1 (el) Χημικες ενωσεις
BRPI0915084B8 (pt) composto, e, composição farmacêutica
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
NO20092637L (no) Fremgangsmater for behandling
EA201170832A1 (ru) Пуриновые соединения
TW200716606A (en) Chemical compounds
TW200800963A (en) Chemical compounds
LT2478907T (lt) Kompozicijos vėžiui gydyti
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
EA201170521A1 (ru) Новые соединения
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
UA107783C2 (en) Isoindoline compounds for use in treating cancer
CY1112889T1 (el) Αναλογα αζετιδινης αναστολεων νουκλεοσιδασης και φωσφορυλασης
UA94129C2 (ru) Соединения для ингибирования митоза
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
UA108743C2 (uk) Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
WO2007097981A3 (en) Alpha carbolines and uses thereof